InflaRx NV (MEX:IFRXN) Research & Development: MXN488.68 Mil (TTM As of Mar. 2026)


MEX:IFRXN InflaRx NV MEX:IFRXN
30 GF Score
Price MXN22.00
! 5 Warning Signs
View Full Analysis

What is InflaRx NV Research & Development?

InflaRx NV MEX:IFRXN 30 Research & Development is MXN488.68 Mil as of Mar. 2026. GuruFocus rates MEX:IFRXN with a GF Score™ of 30/100. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. InflaRx NV's Research & Development for the three months ended in Mar. 2026 was MXN86.95 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was MXN488.68 Mil.

InflaRx NV  (MEX:IFRXN) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

InflaRx NV Research & Development Related Terms

InflaRx NV Research & Development Historical Data

* Premium members only.

The historical data trend for InflaRx NV's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InflaRx NV Research & Development Chart

InflaRx NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 827.47 775.01 759.38 772.29 542.30

InflaRx NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 155.17 156.43 134.37 110.92 86.95
MEX:IFRXN
30GF Score
InflaRx NV MEX:IFRXN
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InflaRx NV Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN488.68 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of MXN488.68 Mil mean?
InflaRx NV (MEX:IFRXN) has a Research & Development of MXN488.68 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on InflaRx NV and its competitors.
Is InflaRx NV's Research & Development too high?
InflaRx NV's current Research & Development is MXN488.68 Mil. Overall, InflaRx NV has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does InflaRx NV's Research & Development compare to IRD and NAUT?
InflaRx NV's Research & Development of MXN488.68 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on InflaRx NV and its competitors. InflaRx NV's current Research & Development is MXN488.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InflaRx NV stock overvalued right now?
InflaRx NV (MEX:IFRXN) has a current Research & Development of MXN488.68 Mil. The current Research & Development is MXN488.68 Mil. InflaRx NV's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For InflaRx NV (MEX:IFRXN), the current Research & Development is MXN488.68 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

InflaRx NV Business Description

Other Exchanges IFRX:USAIF0:Germany
Address Winzerlaer Strasse 2, Jena, DEU, 07745
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
30GF Score

Get the complete analysis for MEX:IFRXN

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN22.00
Price